What are the recommended chemotherapy regimens for adenocarcinoma, including dosing and patient considerations?

Recommended Chemotherapy for Adenocarcinoma

The optimal chemotherapy regimen depends critically on the primary site of adenocarcinoma—for gastric/esophagogastric junction adenocarcinoma use platinum-fluoropyrimidine doublets with checkpoint inhibitors if PD-L1 CPS ≥1 and trastuzumab if HER2-positive; for pancreatic adenocarcinoma use mFOLFIRINOX or gemcitabine plus capecitabine in the adjuvant setting.

Gastric and Esophagogastric Junction Adenocarcinoma

Advanced/Metastatic Disease

For patients with adequate performance status (ECOG 0-2 or KPS ≥60%), systemic therapy provides survival benefit over best supportive care alone (8 vs 5 months OS) 1.

First-line therapy selection:

• Add trastuzumab to chemotherapy backbone if HER2-overexpression positive 1
• Add checkpoint inhibitor to chemotherapy if PD-L1 CPS ≥1 1
• Prefer two-drug cytotoxic regimens (platinum plus fluoropyrimidine) due to lower toxicity 1
• Reserve three-drug regimens only for medically fit patients with excellent performance status and easy access to frequent toxicity monitoring 1

Key patient considerations:

• Patients with KPS <60% or ECOG PS ≥3 should receive palliative/best supportive care only 1
• Regimens for esophageal, EGJ, and gastric adenocarcinoma are interchangeable 1
• Choice should account for performance status, medical comorbidities, and toxicity profile 1

Adjuvant/Perioperative Setting

Perioperative systemic therapy is category 1 for localized gastric cancer 1. Postoperative chemotherapy is recommended following primary D2 lymph node dissection 1.

Pancreatic Adenocarcinoma

Adjuvant Setting (Resected Disease)

For patients with good performance status (ECOG 0-1), mFOLFIRINOX is the preferred regimen 2, 3:

• Dosing: Oxaliplatin 85 mg/m², leucovorin 400 mg/m², irinotecan 150 mg/m² day 1, and 5-FU 2.4 g/m² over 46 hours every 14 days for 12 cycles 3
• Efficacy: Median DFS 21.6 months vs 12.8 months with gemcitabine; median OS 54.4 vs 35.0 months 2
• Toxicity: Grade 3-4 adverse events in 75.9% (vs 52.9% with gemcitabine), but manageable in selected patients 2

Alternative preferred regimen:

• Gemcitabine plus capecitabine (category 1) 2, 4

Other recommended options (when preferred regimens inappropriate):

• Gemcitabine monotherapy (category 1) 2
• 5-FU/leucovorin (category 1) 2
• Capecitabine monotherapy (category 2B, last choice) 2

Critical patient selection: mFOLFIRINOX should only be used in patients meeting PRODIGE trial eligibility—good performance status, R0/R1 resection, postoperative CA 19-9 ≤180 U/mL, no metastases, and no major comorbidities 2. Some panel members emphasize strict adherence to these criteria due to toxicity concerns 2.

Chemoradiation: Not recommended routinely as addition to modern chemotherapy does not improve survival 4. Consider only for positive margins after induction chemotherapy 2. SBRT should only be used within clinical trials 4.

Advanced/Metastatic Disease

Multi-drug combination regimens (FOLFIRINOX or gemcitabine plus nab-paclitaxel) provide survival benefit over single agents 5, 6. Three-drug regimens should be reserved for fit patients or when rapid response needed for symptom control 5.

Common Pitfalls to Avoid

• Do not use mFOLFIRINOX in pancreatic cancer patients with poor performance status or significant comorbidities—toxicity will outweigh benefit 2
• Do not omit HER2 and PD-L1 testing in gastric adenocarcinoma—these determine eligibility for targeted therapy and immunotherapy 1
• Do not use three-drug cytotoxic regimens in gastric cancer without ensuring excellent performance status and frequent toxicity monitoring access 1
• Restage with imaging after systemic chemotherapy if chemoradiation is planned to detect early progression 2
• Evaluate for disease extent prior to adjuvant therapy as some patients experience early recurrence within weeks after surgery 2